Showing results (101-110 of 203) with videos related to

Sort By:
Pageof 21
Ophthalmology|November 25, 2006
Hookworm infestation as a risk factor for Mooren's ulcer in South IndiaJoseph R Zelefsky, Muthaiah Srinivasan, Arunava Kundu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2006
Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trialGuillaume Portier, Dominique Elias, Olivier Bouche, et al.
Annals of Surgical Oncology|April 15, 2006
Current issues in adjuvant treatment of stage II colon cancerThierry André, Daniel Sargent, Josep Tabernero, et al.
International Journal of Technology Assessment in Health Care|October 14, 2014
Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makersOriana Ciani, Sarah Davis, Paul Tappenden, et al.
The Oncologist|March 15, 2026
Benefit-risk balance of S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC)Jean-Christophe Chiem, Hatem Alharazin, Everardo D Saad, et al.
BMC Genomics|August 23, 2008
Comparison of prognostic gene expression signatures for breast cancerBenjamin Haibe-Kains, Christine Desmedt, Fanny Piette, et al.
Clinical Trials (London, England)|October 25, 2023
Design of a clinical trial using generalized pairwise comparisons to test a less intensive treatment regimenMickaël De Backer, Manju Sengar, Vikram Mathews, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 21, 2015
Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple MyelomaPierre Squifflet, Stefan Michiels, David Siegel, et al.
Oncotarget|October 22, 2016
An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinomaJulien Péron, Pascal Roy, Thierry Conroy, et al.
Journal of the National Cancer Institute|March 7, 2019
Assessing Long-Term Survival Benefits of Immune Checkpoint Inhibitors Using the Net Survival BenefitJulien Péron, Alexandre Lambert, Stephane Munier, et al.
Pageof 21